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Abstract
Phenotyping of chronic obstructive pulmonary disease (COPD) with computed tomography (CT) is used
to distinguish between emphysema- and airway-dominated type. The phenotype is reflected in
correlations with lung function measures. Among these, the relative value of body plethysmography
has not been quantified. We addressed this question using CT scans retrospectively collected from
clinical routine in a large COPD cohort. Three hundred and thirty five patients with baseline data of
the German COPD cohort COPD and Systemic Consequences-Comorbidities Network were included. CT
scans were primarily evaluated using a qualitative binary emphysema score. The binary score was positive
for emphysema in 52.5% of patients, and there were significant differences between the positive/negative
groups regarding forced expiratory volume in 1 second (FEV1), FEV1/forced vital capacity (FVC),
intrathoracic gas volume (ITGV), residual volume (RV), specific airway resistance (sRaw), transfer
coefficient (KCO), transfer factor for carbon monoxide (TLCO), age, pack-years, and body mass index
(BMI). Stepwise discriminant analyses revealed the combination of FEV1/FVC, RV, sRaw, and KCO to be
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significantly related to the binary emphysema score. The additional positive predictive value of body
plethysmography, however, was only slightly higher than that of the conventional combination of
spirometry and diffusing capacity, which if taken alone also achieved high predictive values, in contrast
to body plethysmography. The additional information on the presence of CT-diagnosed emphysema as
conferred by body plethysmography appeared to be minor compared to the well-known combination of
spirometry and CO diffusing capacity.
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Introduction
In patients with chronic obstructive pulmonary disease
(COPD) the phenotyping into a predominantly emphy-
sema- or airway-dominated type is generally consid-
ered as important. The diagnosis is usually based on
chest computed tomography (CT) imaging.1,2 In the
case where no such CT data was available, several
studies have evaluated how strongly lung function
parameters correlate with CT findings.3 A useful appli-
cation of lung function would be monitoring of treat-
ment, for example, in patients with alpha-1 antitrypsin
deficiency, which otherwise would require repeated
CT scans.4 Spirometry is a marker for emphysema but
in general its correlation with the degree of emphysema
on CT is weak.5 Transfer factor for carbon monoxide
(TLCO) shows a closer relationship to the amount of
emphysema5 and is also established for treatment mon-
itoring.6 Lung hyperinflation as determined by, for
example, body plethysmography also correlates with
emphysema on CT scans, but the values may differ
from CT-derived volume measures,7 possibly due to
differences in posture as body plethysmography is
commonly performed in sitting position.
In clinical practice, CT scans are performed due to
a variety of indications, possibly with intravenous
application of iodinated contrast media. Thus, the
degree of standardization is low which becomes rele-
vant when CT scans are retrospectively compared.
Moreover, scans may be available only in a propor-
tion of patients with possible emphysema. In contrast,
assessment of emphysema in prospective clinical
studies can be based on CT scans with highly standar-
dized acquisition parameters.8 Therefore, in clinical
practice, the question remains important to which
extent the presence of emphysema can be predicted
from other assessments than CT, especially lung
function. Besides spirometry and CO diffusing capac-
ity, body plethysmography could be informative. The
method seems suited to quantify lung hyperinflation
which is thought to be associated with emphysema but
has not been studied in this respect.
To determine the additional value of body plethys-
mography regarding its predictive power for the pres-
ence or absence of emphysema, we compared this
assessment with spirometry and CO diffusion capac-
ity. Each of the lung function measurements was eval-
uated either alone or in combination with the other
measurements, using a subset of data from the
German COPD cohort COPD and Systemic Conse-
quences-Comorbidities Network (COSYCONET) in
which routine CT scans were available.
Methods
Study population
For this analysis we used visit 1 data of the COSYC-
ONET cohort.9 Only patients with spirometric global
initiative for chronic obstructive lung disease
(GOLD) grade 1–410 or COPD patients at risk (symp-
toms of chronic bronchitis and forced expiratory vol-
ume in 1 second (FEV1)/forced vital capacity (FVC)
 0.7; see below) with CT scans of sufficient quality
and plausible lung function data were included. This
resulted in 335 of 2741 patients (Table 1). The
COSYCONET study was approved by the ethical
committees of all study centers, and all patients gave
their written informed consent.9
Assessments
The patients’ clinical and functional state was
assessed at the first study visit, using a broad panel
of tests that were guided by standard operating
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procedures as defined by the study protocols of
COSYCONET.9 Lung function comprised spirome-
try, body plethysmography, and diffusing capacity for
carbon monoxide (CO).9 From spirometry, FEV1,
FVC, and the FEV1/FVC ratio were chosen for anal-
ysis; from body plethysmography, intrathoracic gas
volume (ITGV), total lung capacity (TLC), and
effective specific airway resistance (sRaw); and
from diffusing capacity, the transfer factor for CO
(TLCO), and the transfer coefficient (KCO). Pre-
dicted values of FEV1, FEV1/FVC, and FVC were
taken from global lung function initiative (GLI),11
values of ITGV and TLC from European Coal and
Steel Community,12 and values of TLCO and KCO
from van der Lee et al.13 All lung function data were
subject to defined quality control procedures.
Evaluation of CT scans
Chest CT scans acquired within 4 years prior to inclu-
sion into the study were collected and submitted to the
central image bank of COSYCONET. Scans with
findings that could hamper the analysis, for example,
lobar pneumonia, were excluded but those obtained
for suspected acute pneumonia were included if nor-
mal with respect to this condition.
CT scans were subjected to a standardized visual
assessment by a chest radiologist with 25 years of
experience in the field (HUK). For this purpose, an
algorithm based on modified guidelines of the COPD
Gene CT Workshop Group2 was applied. The extent
of emphysema was evaluated semiquantitatively with
a five-point scale (<5%, 5–25%, 26–50%, 51–75%,
and >75%) along with the leading type of emphysema
(centrilobular vs. panlobular emphysema) in a lobe-
based approach. In addition, the presence of bronch-
iectases, bronchial wall thickening, centrilobular
nodules, and mosaic attenuation was recorded. More-
over, the prevalence of paraseptal emphysema and
bullae (each for right and left side) was documented,
as well as abnormalities (i.e. collapse or stenosis) of
the trachea or right or left main stem bronchi. On
the basis of these findings, finally, the observer spec-
ified the predominant COPD phenotype (either
emphysema-type or not) in a binary score. The final
score used in the analysis thus comprised emphysema
versus non-emphysema (airway-type or unspecified).
In addition to visual scoring, a software-based eva-
luation of the CT data was performed using an auto-
mated algorithm for the quantification of emphysema
(YACTA (version 1.1.14.1)).14–16 This provided con-
tinuous metrics related to pulmonary emphysema:
Table 1. Baseline characteristics of the subgroups with positive and negative binary emphysema score according to CT.a
Parameter All patients Emphysema Non-Emphysema p Values
N (%) 335 176 (52.5%) 159 (47.5%) —
Gender (m/f) 221/114 115/61 106/53 0.444
Age (y) 64.4 (+8.1) 63.3 (+7.8) 65.6 (+8.3) 0.018b
BMI (kg/m2) 26.2 (+4.9) 24.9 (+4.8) 27.7 (+4.7) <0.001b
Pack-years 48.5 (+38.0) 52.4 (+35.7) 43.9 (+40.2) 0.005b
FEV1%pred 50.0 (+19.6) 44.3 (+16.3) 56.3 (+20.9) <0.001
b
FEV1/FVC%pred 50.6 (+13.3) 45.3 (+10.5) 56.6 (+13.6) <0.001
b
FVC%pred 75.4 (+17.8) 75.4 (+18.8) 75.5 (+16.7) 0.864
TLC%pred 120.5 (+20.5) 126.5 (+20.0) 114.0 (+19.2) <0.001b
RV%pred 182.2 (+56.5) 198.0 (+56.0) 164.7 (+52.0) <0.001b
ITGV%pred 153.7 (+40.2) 166.6 (+38.3) 139.3 (+37.4) <0.001b
sRaweff (kPA  s) 2.39 (+1.62) 2.67 (+1.64) 2.07 (+1.54) <0.001b
TLCO%pred 116.0 (+34.2) 38.8 (+18.5) 55.7 (+ 20.3) <0.001b
KCO%pred 60.6 (+24.4) 49.4 (+18.5) 72.4 (+24.4) <0.001b
GOLD at risk/1/2/3/4 28/19/96/149/43 3/6/44/92/31 25/13/52/57/12 <0.001b
BMI: body mass index; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; GOLD: global initiative for chronic
obstructive lung disease; RV: residual volume; ITGV: intrathoracic gas volume; sRaw: specific airway resistance; KCO: transfer coefficient.
aThe table shows mean values and standard deviations or absolute numbers. Fourth column presents the results of comparisons
between the two groups with positive or negative binary emphysema score. The comparisons between groups were performed by the
Mann–Whitney U test to accommodate for potential deviations from normality or by a w2 test in the case of gender and COPD patients
at risk (abbreviated as at risk) and GOLD grades 1–4.
bp < 0.05.
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(1) the mean lung density (MLD) in Hounsfield Units
(HU), (2) the 15th percentile of the lung density histo-
gram (15TH), (3) the emphysema index (EI) defined as
the volume fraction of emphysema (lung tissue drop-
ping below a density threshold of950 HU) in percent
of total lung volume. In the present analysis, only the
binary emphysema score and the three continuous
scores (MLD, 15TH, and EI) were evaluated.
Statistical analysis
Mean values and standard deviations are given for all
parameters. The values of the two groups were com-
pared using the Mann–Whitney U test, or w2 statistics
and contingency tables, as appropriate. In the multi-
variate analyses, some of the parameters were trans-
formed to achieve a normal distribution or at least a
distribution very close to normal. These transforma-
tions have to be understood as purely statistical tools,
which allowed the application of powerful parametric
methods. Accordingly, the relationship of the binary
emphysema score (emphysema versus non-emphy-
sema) to predictors was analyzed via linear discrimi-
nant analysis. For this purpose, comprehensive sets of
lung function parameters from spirometry, body
plethysmography, and diffusing capacity were cho-
sen. We used a stepwise approach with forward selec-
tion. Body mass index (BMI) was kept in the initial
set of predictors in all models since it might affect
lung volumes. To check the consistency of the results,
analyses were repeated in the form of logistic regres-
sion analyses. The three continuous scores (lung den-
sity, 15th percentile of lung density, and EI) were
analyzed by multiple linear regression with forward
selection. Moreover, the scores derived from the dis-
criminant analyses were used for the construction and
comparison of receiver operating characteristic
curve (ROC curve). Statistical significance was
assumed for p <0.05. Analyses were performed using
the software packages SPSS Statistics 24 (IBM Corp.,
Armonk, New York, USA) and MedCalc (comparison




CT scans that fulfilled the selection criteria were avail-
able in 335 of 2741 patients (Table 1). The binary score
was positive for emphysema in 52.5% of patients
(10.7%, 31.6%, 45.8%, 61.7%, and 72.1% of COPD
patients at risk and with GOLD grades 1–4). The distri-
bution of the binary emphysema score was significantly
different across grades 0–4 (p < 0.001). There were also
significant differences between the two groups regard-
ing FEV1, FEV1/FVC, ITGV, residual volume (RV),
TLC, KCO, TLCO, each in terms of predicted values,
moreover in sRaw, age, pack-years, and BMI (Table 1).
CT scans
CT scans had been performed for a variety of purposes
(among them 53.1% suspected emphysema, 5.1%
COPD, 6.9% suspected tumor, 4.0% suspected pneu-
monia). Frequent values of slice thickness were 1.0mm
(33.6%), 3 mm (11.1%), and 5 mm (26.7%). The num-
ber of contrast-enhanced CT scans was equally distrib-
uted between patients with positive (40.9%) and
negative (42.5%) emphysema score (p ¼ 0.50).
Binary emphysema score
When discriminant analysis was started with the set of
all lung function parameters, KCO%pred, FEV1/
FVC%pred, sRaweff, and RV%pred remained as signif-
icant variables separating the two groups according to
the binary emphysema score (Wilks’ Lambda 0.682,
p < 0.001; specificity 71.9%; sensitivity 77.7%; posi-
tive predictive value 74.9%). All other lung function
parameters and BMI were eliminated in the selection
procedure irrespective of the fact that there were signif-
icant differences between groups (see Table 1). In these
analyses FEV1/FVC%pred was evaluated as square
root, and sRaw as logarithm in order to approximate
a normal distribution; if the untransformed values
were taken, RV was replaced by ITGV with virtually
the same results of classification. The robustness of
the discriminant analysis was checked by bootstrap-
ping (1000-fold repetition). This yielded similar
results as the initial analysis (sensitivity 77.7%, spe-
cificity 71.9%, positive predictive value 74.9%).
When omitting body plethysmography and using
only spirometry and diffusing capacity, KCO%pred,
FEV1/FVC%pred, and FVC%pred remained as sig-
nificant predictors of the binary emphysema score
(specificity 73.7%, sensitivity 76.3%, positive predic-
tive value 75.0%).
When only the diffusing capacity parameters were
used, KCO%pred remained (positive predictive value
71.2%). When only spirometric parameters were used,
FEV1/FVC%pred and BMI remained (positive predic-
tive value 69.8%). When only body plethysmographic
parameters were used, ITGV%pred and BMI remained
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(positive predictive value 61.7%). The combination of
body plethysmography and spirometry or body plethys-
mography and diffusing capacity yielded similar rela-
tionships as spirometry or diffusing capacity alone.
Logistic regression analyses were performed ana-
logous to discriminant analyses and yielded similar
results regarding the selection of parameters. More-
over, the binary emphysema score was not signifi-
cantly related to the administration of intravenous
contrast enhancement, in accordance with the results
of cross-tabulation (see above).
To illustrate these results, ROC analyses were per-
formed (Figure 1); the respective areas under the curve
are given in Table 2. Using the DeLong method for the
comparison of ROC curves, there was no significant
difference between the triple combination of spirome-
try/diffusing capacity/body plethysmography, and the
dual combination of spirometry/diffusing capacity
(p ¼ 0.624). The triple combination was significantly
better than each of the single assessments (p<0.05 each).
Moreover, body plethysmography was inferior to both
spirometry and diffusing capacity (p < 0.05 each).
Continuous scores
Complete and quantitatively plausible data on MLD
were available in 252 patients. Using all lung function
parameters and BMI as predictors of MLD in
stepwise multiple linear regression analyses, FEV1/
FVC%pred, TLC%pred, and BMI (p  0.009 each)
remained significant (R2 ¼ 0.388). Predictors of the
15th percentile were FEV1/FVC%pred, KCO%pred,
BMI (p  0.005 each), as well as ITGV%pred
(p¼ 0.025; R2¼ 0.415). Predictors of the emphysema
index were ITGV%pred, FEV1/FVC%pred,
TLCO%pred, and BMI (p < 0.012 each; R2 ¼
0.356). The relationship between the 15th percentile
and the prediction score derived from multiple regres-
sion is illustrated in Figure 2. When introducing the
presence of contrast enhancement as additional binary
predictor into the regression analysis, this turned out
to be significant (p < 0.05) for MLD, but not for EI
and the 15th percentile of MLD.
Discussion
In the present study, we evaluated the relationship
between lung function tests, especially body plethys-
mography and EIs derived from CT scans. Body
plethysmography was compared with spirometry and
CO diffusing capacity, the well-known parameters
that have been investigated previously.17,18 sRaw and
RV were statistically significantly correlated with a
binary emphysema score, in addition to KCO and
FEV1/FVC. When omitting body plethysmography
and including only spirometry and diffusing capacity,
the same correlation was achieved but with additional
inclusion of FVC from spirometry. When using only
spirometry or diffusing capacity, the predictive power
was lower, and it was lowest when using only body
plethysmography. The results for three continuous EIs
were similar to those of the binary score but the asso-
ciations were weaker. These findings suggest that
spirometry and CO diffusing capacity confer the
majority of lung function-based information on the
presence of CT-diagnosed emphysema, whereas body
plethysmography plays only a secondary role.
When COSYCONET patients were recruited, it
was not possible to perform CT scans prospectively
under standardized conditions, as in other studies.19
Therefore, we had to use non-standardized scans
obtained from clinical routine, many of which were
not optimized for the assessment of emphysema.
Despite these limitations, it was possible to process
the scans in a manner that a binary emphysema score
(emphysema versus non-emphysema) and three con-
tinuous emphysema indices could be evaluated.
Owing to the outstanding experience of the observer,
Figure 1. Receiver operating characteristic (ROC) curves
for different combinations of predictors. This figure shows
the ROC curves for different combinations of predictors,
either spirometry, body plethysmography, and diffusing
capacity (blue); or spirometry and diffusing capacity
(green); or spirometry (brown), diffusing capacity (yellow),
and body plethysmography (purple) separately. The sets of
parameters for the different combinations are given in the
results section, and the corresponding AUC are given in
Table 2. AUC: areas under the curve.
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the visual evaluation of the binary score was probably
less hampered by this lack of standardization than the
continuous indices, whereas the quantitative indices
relied on evaluations of lung density and were
therefore more prone to variation. Heussel et al. have
demonstrated that the intravenous administration of
iodinated contrast media results in an increase of
lung density and a decrease of quantitative emphy-
sema parameters.20 In the present study, the applica-
tion of contrast enhancement influenced some of the
software-based quantitative EIs but was not related
to the binary score. As a consequence, the quantita-
tive indices yielded less conclusive results than the
binary score.
It seems remarkable that despite the lack of stan-
dardization and the fact that up to 4 years occurred
between CT scan and lung function assessment, the
retrospectively collected CT scans still allowed to
identify correlations with lung function that were sim-
ilar to those reported previously for spirometry and
CO diffusing capacity.17,21
To our knowledge, the set of common body
plethysmographic parameters has not been evaluated
for this purpose before, except for two reports includ-
ing the ratio RV/TLC.17,22 In our study, TLC turned
out to be irrelevant and the value of RV was similar to
that of ITGV. RV/TLC, if tentatively included, was
always eliminated from the set of predictors.
Although sRaw and RV turned out to be significant
predictors in addition to the KCO and FEV1/FVC, the
gain in information was small, as illustrated in the
ROC curves. We used the effective value of sRaw
which is more robust than total resistance.23 More-
over, in contrast to other lung function parameters that
were evaluated in terms of % predicted, we used the
Figure 2. Relationship between the 15th percentile and
the prediction score. The figure shows the predicted values
from multivariate regression against the observed values of
the 15th percentile of MLD. The regression equation
comprised KCO%pred, ITGV%pred, FEV1/FVC%pred, and
BMI (see text). The black circles indicate patients with
positive binary emphysema score and the grey circles
indicate patients with negative binary score. MLD: mean
lung density; KCO: transfer coefficient; ITGV: intrathoracic
gas volume; FEV1: forced expiratory volume in 1 second;
FVC: forced vital capacity; BMI: body mass index.







Asymptotic 95% confidence interval
Lower limit Upper limit
Spirometry/CO diffusing capacity/Body
plethysmography
0.832 0.024 0.000 0.785 0.879
Spirometry/ CO diffusing capacity 0.827 0.024 0.000 0.779 0.874
Spirometry 0.772 0.028 0.000 0.718 0.826
Body plethysmography 0.795 0.026 0.000 0.743 0.846
CO diffusing capacity 0.783 0.027 0.000 0.730 0.837
AUC: area under the curve.
aThis table shows the corresponding areas under the curve for the different combinations of predictors, either spirometry, body
plethysmography, and diffusing capacity; or spirometry and diffusing capacity; or spirometry, body plethysmography, and diffusing
capacity separately. The sets of parameters for the different combinations are given in the results section.bNon-parametric assumption.
cNull hypothesis: AUC.
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absolute values, as in adults the dependence on
anthropometric characteristics is absent or weak.
Taken together, these findings suggest that body
plethysmography confers little additional information
on the presence of emphysema, if spirometry and dif-
fusing capacity are already available.
Age and smoking history in terms of pack-years
were always eliminated as predictors. When the bin-
ary score was taken as outcome, BMI was included as
a predictor if spirometry or body plethysmography
were evaluated separately. Probably this was reflected
by the effect of body weight on the volume-related
parameters that remained as predictors. Regarding the
selection of predictors and the ranking of their value,
the results of linear discriminant analysis and logistic
regression analysis were in concordance, underlining
the validity of our statistical findings.
For the continuous CT indices, the results resembled
those obtained for the binary score, but were more
diverse. For the 15th percentile of lung density which
showed the best results in terms of goodness of fit,
FEV1/FVC%pred, ITGV%pred, and KCO%pred again
appeared as significant predictors, in addition to BMI.
Regarding MLD, various results have been published,
including data indicating that the 15th percentile is less
sensitive to changes in lung volume and more robust in
longitudinal studies.24,25 The inclusion of BMI proba-
bly reflected the dependence of lung density on body
mass.26 Due to these weaknesses, we focused on the
binary emphysema score that was based on the visual
inspection of the CT scan by an experienced radiologist
and less dependent on technical variability than the
continuous scores. Indeed it is known that visual
assessment of CT scans of COPD patients can provide
reproducible, substantial information on emphysema
and airway type.27,28
Limitations
Our study is inter alia limited by the fact that subjects
who are most likely to have severe emphysema and
hyperinflation, for example, lung transplantation or
lung volume reduction patients, were excluded from
the study due to the exclusion criteria of “having
undergone major lung surgery.” In these patients,
however, the question of predicting emphysema
solely from lung function data might be of minor
relevance. We also included only 12% of the total
study cohort in the present analysis, thus our findings
primarily apply to this subgroup of patients. Probably
the selection bias associated with this has not
weakened the associations identified in this study,
since the sub-cohort studied showed a slightly greater
impairment of lung function than the total COSYC-
ONET cohort. The major limitation of our study is the
retrospective collection of CT scans obtained for var-
ious clinical indications. It is reasonable to expect
that this contributed to additional variability in the
qualitative and quantitative evaluation which should
have resulted in a weakening of correlations with
lung function parameters. Moreover, up to 4 years
between the CT scan and the study visit were
allowed, which also could have weakened the asso-
ciation with lung function. This may have introduced
some discrepancies between pulmonary function and
CT assessment of emphysema. Irrespective of these
limitations, the correlations found in our analysis
were comparable to those reported in previous stud-
ies with prospective CT scans. We therefore believe
that our conclusions regarding the additional value
of body plethysmography are valid. Importantly, the
binary emphysema score referred to the presence or
absence of emphysema, thus the absence of emphy-
sema did not necessarily mean the presence of an
airway-dominated type.
Conclusions
RV, ITGV, and sRaw derived from body plethysmo-
graphy conferred information on the presence of CT-
diagnosed emphysema but less than spirometry and
CO diffusing capacity. In particular, the additional
information appeared to be minor compared to the
well-known combination of spirometry and CO dif-
fusing capacity. The maximum positive predictive
value was about 75%. Thus, regarding the prediction
of the presence of CT-diagnosed emphysema, the
additional information as conferred by body plethys-
mography appeared to be minor compared to the well-
known combination of spirometry and CO diffusing
capacity. Irrespective of this, information on lung
volumes is still important for therapeutic decisions
in emphysema treatment, for example, regarding lung
volume reduction.
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